Table 3 Secondary efficacy endpoints
Palonosetron (n = 48) | Ondansetron (n = 50) | Difference,% | p-value | |
|---|---|---|---|---|
(95%CI) | ||||
n (%) | n (%) | |||
Complete response | ||||
0-72 h | 15 (31.3) | 13 (26.0) | 5.3 (-12.6, 23.1) | 0.57 |
0-24 h | 15 (31.3) | 15 (30.0) | 1.3 (-17.0, 19.5) | 0.89 |
24-72 h | 43 (89.6) | 41 (82.0) | 7.6 (-6.1, 21.3) | 0.29 |
No emesis | ||||
0-72 h | 34 (70.8) | 26 (52.0) | 18.8 (-0.06, 37.7) | 0.057 |
0-24 h | 34 (70.8) | 29 (58.0) | 12.8 (-5.9, 31.6) | 0.19 |
24-72 h | 45 (93.8) | 44 (88.0) | 5.8 (-5.6, 17.1) | 0.33 |
No additional rescue medication | ||||
0-72 h | 18 (37.5) | 22 (44.0) | -6.5 (-25.9, 12.9) | 0.52 |
0-24 h | 18 (37.5) | 23 (46.0) | -8.5 (-28.0, 11.0) | 0.40 |
24-72 h | 44 (91.7) | 43 (86.0) | 5.7 (-6.7, 18.1) | 0.38 |